Studies have shown that targeting the autocrine cytokine IL-21 in the TFH cells of mouse models of SLE can help suppress the proliferation and development of TFH and Th17 cells, providing a treatment for SLE (142). Here, IL21 is linked to systemic lupus erythematosus.